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This year, the Nobel Prize in Physiology or 
M e d i c i n e  g o e s  t o  D r s .  M a r i o  R .  C a p e c c h i ,  M a r t i n  J .  
Evans and Oliver Smithies for their discoveries of 
principles for introducing specific gene modifications 
in mice by the use of embryonic stem (ES) cells. This 
technology, commonly referred to as gene targeting or 
knockout, is based on homologous recombination 
between DNA sequences residing in the chromosome 
and newly introduced DNA to mutate any genes of 
interesting in mouse genome [1].   
Twenty years ago, Capecchi and Smithies 
reported the targeted disruption of the 
hypoxanthine-guanine phosphoribosyl transferase 
gene (Hprt) [2], and the targeted correction of a 
defective  Hprt allele [3], respectively, using the ES 
technology developed by Evans [4]. Since then, gene 
targeting has proven to be a powerful means of 
precisely manipulating the mammalian genome, 
generating at least ten thousand mutant mouse stains. 
Studies of these mutant mice have yielded enormously 
useful information in virtually all fields of biological 
and biomedical sciences. Indeed, gene targeting in ES 
cells can theoretically be used to generate mutant mice 
for all genes in the near future. 
Dr. Capecchi’s ground-breaking work for gene 
targeting started well before 1987. In 1980, he 
demonstrated high efficiency of transformation by 
directly microinjecting plasmid DNA into cultured 
mammalian cells [5]. This work led to his important 
conclusion that mammalian somatic cells possess an 
efficient enzymatic machinery for mediating 
homologous recombination [6]. He reasoned that if this 
machinery could be efficient for homologous 
recombination between a newly introduced DNA 
molecule and the endogenous DNA sequence, any 
host gene could be mutated. To demonstrate this 
principle, he generated recipient cell lines carrying an 
artificial target, a defective neomycin resistance gene 
that was stably integrated into host chromosome, and 
was able to repair it by injecting the same gene 
carrying a different mutation into the nucleus of these 
cells [7]. The correction occurred in one cell per 1,000 
injected cells, a relatively high frequency, which makes 
it possible to use homologous recombination to 
manipulate endogenous genes of the mammalian 
genome. 
These studies led to his successful targeted 
disruption of the first endogenous gene, Hprt, in ES 
cells in 1987, as mentioned earlier [2]. In this important 
study, Drs. Thomas and Capecchi used both 
replacement and insertional vectors to introduce a 
neomycin resistance (neor) gene into exon 8 of the Hprt 
gene, showing that clones of transfected cells had lost 
HPRT function (becoming 6-TG resistant), and had 
gained Neor activity. Therefore, the HPRT-deficient 
cells could be easily selected. In their paper, they 
concluded "It is hoped that this combination of using 
ES cells as the recipient cell line and site-specific 
mutagenesis achieved by gene targeting will provide 
the means for generating mice of any desired 
genotype” [2].   
However, a technical obstacle has to be overcome 
to achieve this goal because unlike Hprt, none of the 
other genes has a selective advantage after disruption. 
To solve this, Drs. Mansour, Thomas and Capecchi 
developed a strategy, called “Positive-Negative 
Selection” for enriching ES cells containing a targeted 
disruption of any transfected gene [8]. Dr. Capecchi 
also provided critical improvements in targeting 
efficiencies and accuracy [1, 9-11]. Many human 
disease-associated mutations are point mutations 
involving single nucleotide change. Introduction of 
these types of mutation is a challenge in the early 
stages of gene targeting. Using Hprt and the cystic 
fibrosis transmembrane conductance regulator (Cftr) 
genes, Capecchi and colleagues demonstrated that 
specific alterations (i.e. the F508 of CFTR, small 
deletion or insertion,  and later, a loxP site for 
conditional mutations) that are placed several kb away 
from the selection marker could be co-transferred into 
ES cells through a double crossover event [12]. 
Importantly, they demonstrated that targeting 
efficiencies were strongly dependent upon the extent 
of homology between exogenous and endogenous 
DNA sequences, and that targeting vectors prepared 
from isogenic DNA targeted four to five times more 
efficiently than did the corresponding vectors 
prepared from nonisogenic DNA [10]. Thus, since Int. J. Biol. Sci. 2007, 3 
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then, the proper length of an isogenic targeting 
construct combined with the powerful 
“Positive-Negative Selection” has been the most 
widely used technique for mutating hundreds and 
thousands of genes in the mouse. 
As a former PhD student of Dr. Capecchi (from 
1986 to 1992), I have a special reason to celebrate this 
long awaited, and most prestigious and honorable 
prize to him. I can hardly describe how excited I was 
when I first heard that Dr. Capecchi has won the 2007 
Nobel Prize in Physiology or Medicine. I felt that I was 
very lucky and honored to be one of his former 
students!  
Dr. Capecchi’s success sets an example for new 
generations of scientists. He had a difficult childhood, 
wandering in war-time Italy. He could not read and 
write until 9 years of age, when his mother found him 
on street and his uncle brought him to the USA. When 
talking about his childhood, this resourcefulness, as he 
put it, served as “the drive to keep yourself, maintain 
yourself, and survive”. “And I think now I'm also very 
grateful, in a sense it's fantastic. I mean most children 
didn't make it, I think I was extremely lucky” [13].  
Indeed, Mario was extremely lucky after he arrived in 
USA, finishing his schooling and having a marvelous 
opportunity to be trained by James Watson and Walter 
Gilbert, two Nobel laureates, for his graduate work!  
His early experiences made him more 
independent of outside support and able to use his 
own resources wisely to get through life. Indeed, 
when his initial grant proposal to test the feasibility of 
gene targeting in mammalian cells was rejected, Mario 
managed to continue the work using limited funds 
saved from other projects. Even after he had adequate 
funds, receiving millions after the publication of the 
Cell paper in 1987, his budgets were carefully 
managed. He knows how important it is to get every 
dollar working for the research projects. I remember in 
1991 when we moved our laboratory from the Biology 
Building to a new building sponsored by Howard 
Hughes Medical Institute, several students and I 
discarded some old or partially damaged equipment, 
but Mario requested us to pick them up and move to 
the new laboratory. On the other hand, when Harvard 
Medical School tried to recruit him in 1989 with better 
conditions, he declined it. He told us that the condition 
of University of Utah was good enough for all the 
experiments he would like to perform.  
Now, gene targeting has reached a very fruitful 
stage, with approximately a half of all genes in mouse 
genome (about 22,400 genes) mutated. Targeting 
strategies have been expanded to all different kinds of 
modifications, including point mutations, isoform 
deletions, mutant allele correction, large pieces of 
chromosomal DNA insertion and deletion, tissue 
specific disruption combined with spatial and 
temporal regulation and so on. The ability to generate 
mouse models with predictable phenotypes will 
continue to have a major impact on studies of all 
phases of development, immunology, neurobiology, 
oncology, physiology, metabolism, and human 
diseases. In addition to the improvement of the human 
health, gene targeting is also, in theory, applicable to 
species from which totipotent ES cells can be 
established, and therefore has a potential to the 
improvement of domestic animals and plants.  
The future of gene targeting is bright, although 
there is a long way to achieve all of these goals. Mario 
used to be a long distance runner, running about 8 
miles each day. Apparently, he could not keep up this 
physical activity forever, but he remains a front-runner 
in science. Several months ago, we had a proposal to 
have a symposium to celebrate his 70 years 
anniversary in October of 2007. He told us that it was 
not the right time to celebrate because it might give 
people impression that he would retire soon. He 
would like to continue to work until 79 years of age. 
Now, with his Nobel Prize, it is the right time and we 
have a great reason to celebrate. Mario, 
congratulations on your achievement and great award! 
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